Research and Publications

Alongside my clinical practice, I am actively involved in research aimed at improving the diagnosis and treatment of prostate cancer. Contributing to national clinical trials and academic work keeps my practice engaged with the latest evidence and the evolution of prostate cancer treatment.

Clinical trial involvement

Principal Investigator (Buckinghamshire Healthcare NHS Trust) — IP2-ATLANTA prostate cancer trial

IP2-ATLANTA is a national, multicentre phase II randomised controlled trial, led by Professor Hashim Ahmed at Imperial College London and supported by Prostate Cancer UK. It is investigating whether treating the prostate itself — by surgery, radiotherapy or minimally invasive ablation — may benefit men who have been newly diagnosed with prostate cancer that has already spread beyond the gland (metastatic hormone-sensitive prostate cancer), in addition to the standard drug treatments these men receive. The aim is to find out whether addressing the original tumour can help control the disease for longer; this is a research question the trial is designed to answer, not an established treatment.

As Principal Investigator at Buckinghamshire Healthcare NHS Trust, I lead this study locally, enabling eligible NHS patients in Buckinghamshire to take part in this nationally important research.

This is an NHS research study with specific eligibility criteria, assessed by the clinical team — it is not a private treatment. Men who think they may be eligible should speak to their NHS urology or oncology team.

Publications

In addition to patient-facing content, I have published extensively in peer-reviewed medical journals throughout my career. My research has been cited over 1,000 times in academic literature.

Please see my full list of publications on Google Scholar and ResearchGate

Laparoscopic live donor nephrectomy.

Haldar NA, Cranston DW.Transplantation. 2000 Jun 15;69(11):2237-8. doi: 10.1097/00007890-200006150-00001.PMID: 10868617

Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation.

Marsh HP, Haldar NA, Bunce M, Marshall SE, le Monier K, Winsey SL, Christodoulos K, Cranston D, Welsh KI, Harris AL.Br J Cancer. 2003 Sep 15;89(6):1096-101. doi: 10.1038/sj.bjc.6601165.

Perioperative outcomes of 6042 nephrectomies in 2012: surgeon-reported results in the UK from the British Association of Urological Surgeons (BAUS) nephrectomy database.

Henderson JM, Fowler S, Joyce A, Dickinson A, Keeley FX; BAUS.BJU Int. 2015 Jan;115(1):121-6. doi: 10.1111/bju.12770. Epub 2014 Jul 27.

How reliable is a vasectomy? Long-term follow-up of vasectomised men.

Haldar N, Cranston D, Turner E, MacKenzie I, Guillebaud J.Lancet. 2000 Jul 1;356(9223):43-4. doi: 10.1016/S0140-6736(00)02436-3.

Donor cytokine genotype influences the development of acute rejection after renal transplantation.

Marshall SE, McLaren AJ, McKinney EF, Bird TG, Haldar NA, Bunce M, Morris PJ, Welsh KI.Transplantation. 2001 Feb 15;71(3):469-76. doi: 10.1097/00007890-200102150-00022.

The impact of recipient cytokine genotype on acute rejection after renal transplantation.

Marshall SE, McLaren AJ, Haldar NA, Bunce M, Morris PJ, Welsh KI.Transplantation. 2000 Nov 27;70(10):1485-91. doi: 10.1097/00007890-200011270-00016.

Is renal graft survival predetermined by the recipient’s cytokine profile?

Haldar NA, McLaren A, Marshall SE, Morris PJ, Welsh KI.Transplant Proc. 1999 Feb-Mar;31(1-2):289-90. doi: 10.1016/s0041-1345(98)01630-3.

A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer.

Winsey SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, Harris AL, Wojnarowska F, Welsh KI.Cancer Res. 2000 Oct 15;60(20):5612-6.

Glutathione S-transferase polymorphisms and skin cancer after renal transplantation.

Marshall SE, Bordea C, Haldar NA, Mullighan CG, Wojnarowska F, Morris PJ, Welsh KI.Kidney Int. 2000 Nov;58(5):2186-93. doi: 10.1111/j.1523-1755.2000.00392.x.

Urosepsis and bacteraemia caused by antibiotic-resistant organisms after transrectal ultrasonography-guided prostate biopsy.

Hadway P, Barrett LK, Waghorn DJ, Hasan K, Bdesha A, Haldar N, Kelleher J

The impact of endothelial nitric oxide synthase polymorphisms on long-term renal allograft outcome.

Shenker NS, Haldar NA, Reilly JJ, Bunce M, Welsh KI, Marshall SE.Transpl Int. 2003 Jun;16(6):391-5. doi: 10.1007/s00147-003-0557-7. Epub 2003 Mar 26.

The impact of the two-week wait rule on the diagnosis and management of bladder cancer in a single UK institution.

Blick C, Bailey D, Haldar N, Bdesha A, Kelleher J, Muneer A.Ann R Coll Surg Engl. 2010 Jan;92(1):46-50. doi: 10.1308/003588410X12518836440207.

Adhesion molecule polymorphisms in chronic renal allograft failure.

McLaren AJ, Marshall SE, Haldar NA, Mullighan CG, Fuggle SV, Morris PJ, Welsh KI.Kidney Int. 1999 May;55(5):1977-82. doi: 10.1046/j.1523-1755.1999.00427.x.

A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis.

Satsangi J, Chapman RW, Haldar N, Donaldson P, Mitchell S, Simmons J, Norris S, Marshall SE, Bell JI, Jewell DP, Welsh KI.Gastroenterology. 2001 Jul;121(1):124-30. doi: 10.1053/gast.2001.25527.

Oxygen free radical scavenger enzyme polymorphisms in systemic sclerosis.

Tikly M, Marshall SE, Haldar NA, Gulumian M, Wordsworth P, Welsh KI.Free Radic Biol Med. 2004 Jun 1;36(11):1403-7. doi: 10.1016/j.freeradbiomed.2004.02.079.PMID: 15135176

Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers.

McKinney EF, Walton RT, Yudkin P, Fuller A, Haldar NA, Mant D, Murphy M, Welsh KI, Marshall SE.Pharmacogenetics. 2000 Aug;10(6):483-91. doi: 10.1097/00008571-200008000-00001.

Patents

I hold two patents from Isis Innovation Limited, the commercialisation arm of Oxford University:

• Genetic determinant for chronic inflammatory disease (Patent WO 0171030, 2001)
• A genetic determinant for malignant melanoma (Patent WO 0162964, 2001)